A groundbreaking new drug, Daraxonrasib, is now available at Nebraska Medicine for pancreatic cancer patients who’ve failed traditional chemo—early results show it can double survival time while preserving quality of life. Though not yet FDA approved, it’s being offered through an expanded access program, offering hope to those with limited options. Former Senator Ben Sasse’s trial experience underscores the human impact: every extra day matters. This is a major leap forward in a field long starved of progress, proving that relentless research can deliver real, life-changing hope.

Listen in comfort:
Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn.

Advertise on DNN:
advertise@thednn.ai

This is an automated, high-level news summary based on public reporting.
Report issues to feedback@thednn.ai.

View sources & latest updates:
https://sources.thednn.ai/cc1ff273a3ac1513

Rss Apple Podcaster
Podden och tillhörande omslagsbild på den här sidan tillhör The Daily News Now!. Innehållet i podden är skapat av The Daily News Now! och inte av, eller tillsammans med, Poddtoppen.